Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance

A legfontosabb adatok

Ki végzi
Nanjing Medical University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
300 fő, tervezett
Kezdés
2026. okt. 22.
Várható befejezés
2029. okt. 20.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Aged 18-80 years, regardless of sex
  • Diagnosis of pancreatic ductal adenocarcinoma (PDAC) or its variants confirmed by imaging and/or pathological examination
  • Meeting at least one of the following criteria:
  • Liver metastasis from PDAC confirmed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) at initial diagnosis or during the disease course
  • No evidence of liver metastasis at initial diagnosis, followed by curative-intent surgical resection and planned postoperative surveillance for liver metastasis
  • Availability of sufficient clinical information, including demographic characteristics, medical history, imaging and/or pathological findings, treatment information, liver metastasis status, and follow-up outcomes
  • Availability of a unique study identification code to ensure patient traceability and data linkage
  • For prospective enrollment and biospecimen collection, voluntary provision of written informed consent by the patient or their legally authorized representative, as required by the approved study protocol

Ki nem vehet részt

  • Concomitant diagnosis of other malignant tumors
  • Receipt of preoperative systemic antitumor therapy (neoadjuvant therapy) before curative-intent surgical resection, for patients in the resection subgroup
  • Severe cardiac, pulmonary, hepatic, or renal dysfunction
  • Active infectious diseases
  • Severe coagulation disorders, contraindications to blood collection, or an unacceptably high risk associated with blood collection as assessed by the investigator
  • Pregnancy or breastfeeding

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis, and liver metastasis is a major contributor to treatment failure and reduced survival. Due to the complex mechanisms underlying tumor progression and metastasis, effective early diagnostic biomarkers and targeted therapeutic strategies remain limited. This study aims to investigate the molecular mechanisms underlying PDAC progression and liver metastasis, identify potential biomarkers for early risk prediction and prognostic assessment, and explore novel therapeutic targets to facilitate precision diagnosis and treatment.

A teljes eredeti leírásKevesebb

Participants will be required to:

* Provide histopathologically confirmed primary PDAC tissue and liver metastatic tissue, together with the corresponding adjacent non-tumor pancreatic tissue * Undergo regular follow-up visits for monitoring and data collection. * Allow access to their medical records for relevant clinical information.

A vizsgálat 2 csoportja

  • PDAC With Liver Metastasis

    This cohort includes patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) with liver metastasis confirmed by contrast-enhanced CT or MRI at initial diagnosis or during treatment. Clinical characteristics, laboratory findings, imaging data, pathological features, treatment information, and follow-up outcomes will be collected. Available biospecimens may include primary pancreatic tumor tissue, liver metastatic tissue, corresponding adjacent non-tumor pancreatic tissue, normal liver tissue, and peripheral blood samples. No study-assigned interventions will be administered, and all diagnostic and therapeutic decisions will follow routine clinical practice.

  • Patients With Pancreatic Ductal Adenocarcinoma

    This cohort includes patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) who meet the predefined eligibility criteria. The cohort includes patients with synchronous liver metastasis at initial diagnosis and those without liver metastasis at baseline who undergo curative-intent surgical resection and are followed for the development of postoperative liver metastasis. Clinical characteristics, pathological findings, imaging data, treatment information, available biospecimens, and longitudinal follow-up outcomes will be collected. The primary outcome is the occurrence of liver metastasis within 12 months after curative-intent resection among eligible patients without liver metastasis at baseline. No study-assigned interventions will be administered, and all treatment decisions will follow routine clinical practice.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Potential Regulatory Mechanisms Underlying the Progression of Pancreatic Ductal Adenocarcinoma and Clinical Significance: A Multicenter Exploratory Study
Illeszkedési kérdések
Forrás: NCT07933952: ki vehet részt
A regiszteradat frissítve
2026. november 12.